Joshua Greally has spent over 12 years in drug discovery, starting in small molecule medicinal chemistry and quickly moving into specialize in the development of conjugate therapies. On joining Sygnature discovery Josh’s combined academic and industry experience now informs his work at the interface of science and strategy, where he leads Antibody–Drug Conjugate (ADC) initiatives and supports scientific business development. Driven by a commitment to translating innovation into meaningful therapeutic advances, Joshua is focused on contributing to the development of next‑generation ADC therapies.